Human antibody against FAP-ALPHA

By developing specific all-human antibodies and antigen binding fragments, the problem of poor therapeutic effects of existing FAPα-targeted drugs has been solved, efficient binding and targeting of FAPα is achieved, and new treatment of tumors and rheumatoid joints is provided. The method of inflammation.

CN118974258APending Publication Date: 2024-11-15LEPU BIOPHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202280092987.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-30
Filing Date
2022-12-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing FAPα-targeted drugs have not been observed in tumor therapy, and the minimal expression of FAPα in healthy tissues limits its therapeutic value, and FAPα in RA fibroblast-like synovial cells The high expression of the cells is related to the destruction of extracellular matrix and lacks effective inhibitory measures.

Method used

Specific all-human antibody and antigen binding fragments were developed with high affinity to bind to the FAPα protein for the treatment of diseases associated with FAPα expression, including tumors and rheumatoid arthritis. These antibodies contain heavy chain variable regions and light chain variable regions, and specific CDR sequences ensure high affinity and specificity for FAPα.

Benefits of technology

Achieving effective binding and targeting of FAPα, with potential therapeutic value, provides new Treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005020664810000211
    Figure BDA0005020664810000211
  • Figure BDA0005020664810000221
    Figure BDA0005020664810000221
  • Figure BDA0005020664810000231
    Figure BDA0005020664810000231
Patent Text Reader

Abstract

The present disclosure provides fully human anti-FAP [alpha] antibodies and variants thereof that have further optimized CDR sequences. The novel disclosed antibodies exhibit high affinity for FAPa protein, and are useful for the treatment of cancer and inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] FAPα (fibroblast activation protein alpha, FAP, FAPA, or FAPalpha) is an intramembrane-integrated gelatinase that is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are tumor stromal cells and the most important component of the tumor microenvironment. CAFs regulate multiple aspects of tumor growth, including tumorigenesis, angiogenesis, metastasis, immunosuppression, and promotion of drug resistance. FAPα is thought to be involved in the regulation of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.

[0002] FAPα is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. FAPα expression has been reported to be associated with higher tumor grade and poor overall survival in solid tumors in a variety of human cancer types, including gastric cancer, pancreatic cancer, breast cancer, and colon cancer. Currently, FAP inhibitors have been widely used in tumor PET / computed tomography (CT) imaging. In theory, FAP-targeted drugs can also serve as promising therapeutic targets for inhibiting tumor progression and metastasis. However, no satisfactory therapeutic effects have been observed so far. Therefore, considering the important role of FAPα in tumor progression and its rare expression in healthy tissues, the therapeutic value of FAPα in cancer treatment deserves further investigation.

[0003] In addition, it was observed that high expression of FAPα in RA (rheumatoid arthritis) fibroblast-like synoviocytes (FLS) was associated with the invasive phenotype of FLS, accompanied by high proliferation and destruction of the extracellular matrix. Therefore, FAPα can be considered a therapeutic target to inhibit the destructive potential of FLS. Summary of the invention

[0004] In various embodiments, the present disclosure provides fully human antibodies and antigen-binding fragments that are specific for human FAPα protein. Experimental results show that these newly discovered antibodies can effectively and specifically bind to human FAPα protein. In addition, most of them retain a strong affinity for FAPα protein expressed on the cell surface and can be appropriately used to treat diseases associated with FAPα expression.

[0005] According to one embodiment of the present disclosure, an antibody or an antigen-binding fragment thereof is provided, which is specific to human fibroblast activation protein α (FAPα) protein and comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region (VL) comprising VL CDR1, VL CDR2 and VL CDR3.

[0006] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:67; the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:15-17 and 43-55; the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:20-23, 25, 59 and 60; the amino acid sequence of the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:68; the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO:31; and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO:69.

[0007] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:67; the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:15 and 43-48; the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:20, 59 and 60; the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:68; the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO:31; and the VLCDR3 comprises the amino acid sequence as shown in SEQ ID NO:69. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 11; the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 43-48; the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 59 and 60; the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 27; the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31; the VL CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 61 and 62.

[0008] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:67; the VHCDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:16 and 49-54; the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO:21; the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:68; the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO:31; and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO:69. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:12; the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16 and 49-54; the VHCDR3 comprises the amino acid sequence shown in SEQ ID NO:21; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:28; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:35, 63 and 64.

[0009] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 67; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 68; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 31; and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 69. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 31; and the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 61, and 62.

[0010] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; the VHCDR2 comprises the amino acid sequence shown in SEQ ID NO:17 or 55; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:23; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:69.

[0011] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:12; the VHCDR2 comprises the amino acid sequence as shown in SEQ ID NO:17 or 55; the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO:23; the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:27; the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO:31; the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:36, 65 and 66.

[0012] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 67; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 68; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 31; and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 69. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 31; and the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 61, and 62.

[0013] Also provided are multispecific antibodies comprising an antigen-binding fragment of the disclosure and one or more antibodies or antigen-binding fragments having binding specificity for a target antigen other than FAPa.

[0014] In another embodiment, a chimeric antigen receptor (CAR) is also provided, which comprises an antigen binding fragment of the present disclosure, a transmembrane domain, a co-stimulatory domain and a CD3ξ intracellular domain.

[0015] Also provided are polynucleotides encoding antibodies, antigen-binding fragments thereof, or CARs of the present disclosure. In some embodiments, the polynucleotide is mRNA, which may be optionally chemically modified.

[0016] Also provided are methods and uses for treating cancer and inflammatory disorders using the antibodies or antigen-binding fragments thereof of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 ELISA binding activity of all tested antibodies to human and mouse FAPa proteins is shown.

[0018] Figure 2 It was shown that, except for I38 and J59, the tested antibodies bound with high affinity to the FAPα protein on CHO-K1-hFAPα cells.

[0019] Figure 3 Biacore kinetic test results for each antibody tested. DETAILED DESCRIPTION

[0020] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0021] definition

[0022] It should be noted that the term "a" or "an" entity refers to one or more of the entity; for example, "an antibody" is understood to represent one or more antibodies. Therefore, the terms "a" (or "an"), "one or more" and "at least one" (at least one) can be used interchangeably herein.

[0023] As used herein, "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that can specifically recognize and bind to an antigen. The antibody can be a full-length antibody, any antigen-binding fragment, or a single-chain form thereof. Therefore, the term "antibody" includes any protein or peptide that comprises at least a portion of an immunoglobulin molecule, which has the biological activity of binding to an antigen. These examples include, but are not limited to, the complementarity determining regions (CDRs) of a heavy or light chain or its ligand-binding portion, a heavy or light chain variable region, a heavy or light chain constant region, a framework (FR) region, or any portion thereof, or at least a portion of a binding protein.

[0024] As used herein, the term "antibody fragment" or "antigen-binding fragment" refers to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Regardless of the structure, an antibody fragment will bind to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, mirror-image homomers, and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts similarly to an antibody by binding to a specific antigen to form a complex.

[0025] The term antibody includes a wide variety of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (γ, μ, α, δ, ε), as well as some subclasses therein (e.g., γ1-γ4). The nature of this chain determines the "class" of the antibody, which is IgG, IgM, IgA, IgG, or IgE, respectively.

[0026] Immunoglobulin subclasses (isotypes) such as IgG1, IgG2, IgG3, IgG4, IgG5, etc. have been fully characterized and are known to have functional specificity. Based on the present disclosure, those skilled in the art can easily identify modified versions of each class and subtype, and therefore, these modified versions also fall within the scope of the present disclosure. All immunoglobulin classes are obviously within the scope of the present disclosure, and the following discussion will focus on IgG class immunoglobulin molecules. For IgG, a standard immunoglobulin molecule includes two identical light chain polypeptides with a molecular weight of approximately 23,000 daltons, and two identical heavy chain polypeptides with a molecular weight of 53,000-70,000 daltons. These four chains are usually connected by disulfide bonds in a "Y" configuration, in which the light chain surrounds the heavy chain, starting from the mouth of the "Y" and extending to the variable region.

[0027] The antibodies, antigen-binding polypeptides, variants or derivatives thereof disclosed herein include, but are not limited to, polyclonal antibodies, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, primate antibodies or chimeric antibodies, single-chain antibodies, epitope binding fragments, such as Fab, Fab' and F(ab')2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), fragments comprising VK or VH domains, fragments produced by Fab expression libraries, and anti-specific (anti-Id) antibodies (e.g., anti-Id antibodies including LIGHT antibodies disclosed herein). The immunoglobulin or antibody molecule disclosed herein may be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), category (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecules.

[0028] Anti-FAPα antibody

[0029] As demonstrated in the attached experimental examples, the inventors have successfully prepared fully human FAPα antibodies G14, G52, I30, I37, I38, J40 and J59 (Table 1), all of which have high binding affinity to human FAPα protein. In addition, at least five of these molecules (G14, G52, I30, I37 and J40) retain super strong affinity with FAPα on the cell surface and are therefore suitable molecules for therapeutic applications. Further experiments showed that these antibodies all target the same epitope on FAPα, which is also the epitope recognized by the benchmark anti-FAPα antibody. Interestingly, these antibodies have highly homologous VH CDR1 and all VL CDR sequences.

[0030] According to one embodiment of the present disclosure, an antibody or an antigen-binding fragment thereof is provided. In some embodiments, the antibody or its antigen-binding fragment has binding specificity to human FAPα protein. In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable region (VH), which comprises VH CDR1, VH CDR2 and VH CDR3, and a light chain variable region (VL), which comprises VL CDR1, VL CDR2 and VL CDR3.

[0031] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:15-17 and 39-47, the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:20-23, 25 and 51, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:68, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO:69.

[0032] As shown in Table 1C, SEQ ID NO:67 has a SYAMX sequence, wherein X is H or S. SEQ ID NO:68 has a RASQGX1X2SWLA sequence, wherein X1 is I or V, and X2 is G or S. SEQ ID NO:69 has a QQAX1X2FPX3T sequence, wherein X1 is N or W, X2 is A or S, and X3 is L, P or V.

[0033] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody G14. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 15 and 43-48, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 20 and 51, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 68, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 69.

[0034] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:11, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO:15, the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:20, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:27, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:34.

[0035] In some embodiments, one or more CDRs are PTM (post-translational modification) to reduce risk. In some embodiments, the VH CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 11, the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15 and 43-48, the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 59 and 60, the VL CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 27, the VL CDR2 comprises an amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 61 and 62.

[0036] In some embodiments, VH comprises an amino acid sequence as shown in SEQ ID NO: 1 or a sequence having at least 75%, 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 1, while retaining the VH CDR of SEQ ID NO: 1 or a PTM risk re-evaluated version thereof. In some embodiments, VL comprises an amino acid sequence as shown in SEQ ID NO: 2 or a sequence having at least 75%, 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 2, while retaining the VL CDR of SEQ ID NO: 2 or a PTM risk re-evaluated version thereof. In some embodiments, VH comprises an amino acid sequence as shown in SEQ ID NO: 1, and VL comprises an amino acid sequence as shown in SEQ ID NO: 2. In certain embodiments, antibodies and antigen-binding fragments that bind to the same epitope as G14 on FAPα are also provided. In certain embodiments, antibodies and antigen-binding fragments that compete with G14 for binding to FAPα are also provided.

[0037] In some embodiments, antibodies and antigen-binding fragments thereof that bind to the same epitope of FAPα as G14 are also provided. In some embodiments, antibodies and antigen-binding fragments thereof that compete with G14 in binding to FAPα are also provided.

[0038] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody G52. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 16 and 49-54, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 21, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 68, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 69.

[0039] In some embodiments, the VH CDR1 comprises the amino acid sequence shown as SEQ ID NO:12, the VH CDR2 comprises the amino acid sequence shown as SEQ ID NO:16, the VH CDR3 comprises the amino acid sequence shown as SEQ ID NO:21, the VL CDR1 comprises the amino acid sequence shown as SEQ ID NO:28, the VL CDR2 comprises the amino acid sequence shown as SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence shown as SEQ ID NO:35.

[0040] In some embodiments, one or more CDRs undergo PTM (post-translational modification) to reduce risk. In some embodiments, the VH CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 12, the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 16 and 49-54, the VH CDR3 comprises an amino acid sequence as shown in SEQ ID NO: 21, the VL CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 28, the VL CDR2 comprises an amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 35, 63 and 64.

[0041] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:3, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:3, while retaining the VH CDRs of SEQ ID NO:3, or a PTM risk re-evaluated version thereof. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO:4, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:4, while retaining the VL CDRs of SEQ ID NO:4, or a PTM risk re-evaluated version thereof. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:3, and the VL comprises an amino acid sequence as set forth in SEQ ID NO:4.

[0042] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as G52 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with G52 for binding to FAPα are also provided.

[0043] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody I30. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 17 and 55, the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 68, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 69.

[0044] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:12, the VHCDR2 comprises the amino acid sequence shown in SEQ ID NO:17, the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:22, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:27, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:34.

[0045] In some embodiments, one or more CDRs undergo PTM (post-translational modification) to reduce risk. In certain embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 12, the VH CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 17 or 55, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 22, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 27, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 61 and 62.

[0046] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:5, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:5, while retaining the VH CDRs of SEQ ID NO:5 or a PTM risk re-evaluated version thereof. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO:6, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:6, while retaining the VL CDRs of SEQ ID NO:6 or a PTM risk re-evaluated version thereof. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:5, and the VL comprises an amino acid sequence as set forth in SEQ ID NO:6.

[0047] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as I30 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with I30 for binding to FAPα are also provided.

[0048] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody I37. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 17 and 55, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 23, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 68, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 69.

[0049] In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:12, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO:17, the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:23, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:27, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:36.

[0050] In some embodiments, one or more CDRs undergo PTM (post-translational modification) to reduce risk. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 12, the VH CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 17 or 55, the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 23, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 27, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 36, 65 and 66.

[0051] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:7, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:7, while retaining the VH CDRs of SEQ ID NO:7, or a PTM risk re-evaluated version thereof. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO:8, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:8, while retaining the VL CDRs of SEQ ID NO:8, or a PTM risk re-evaluated version thereof. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO:7, and the VL comprises an amino acid sequence as set forth in SEQ ID NO:8.

[0052] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as I37 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with I37 for binding to FAPα are also provided.

[0053] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody J40. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 67, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 17 and 55, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 25, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 68, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 69.

[0054] In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO:12, the VH CDR2 comprises the amino acid sequence as shown in SEQ ID NO:17, the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:25, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO:27, the VLCDR2 comprises the amino acid sequence as shown in SEQ ID NO:31, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO:34.

[0055] In some embodiments, one or more CDRs are PTM (post-translational modification) to reduce risk. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 12, the VH CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 17 or 55, the VH CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 25, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 27, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 31, and the VL CDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 34, 61 and 62.

[0056] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 9, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 9, while retaining the VH CDRs of SEQ ID NO: 9, or a PTM risk re-evaluated version thereof. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO: 10, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 10, while retaining the VL CDRs of SEQ ID NO: 10, or a PTM risk re-evaluated version thereof. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 9, and the VL comprises an amino acid sequence as set forth in SEQ ID NO: 10.

[0057] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as J40 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with J40 for binding to FAPα are also provided.

[0058] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody I38. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 13, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 18, the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 24, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 29, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 32, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 37.

[0059] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 39, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto, while retaining the VH CDRs or a PTM risk reassessed version thereof of SEQ ID NO: 39. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO: 40, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto, while retaining the VL CDRs or a PTM risk reassessed version thereof of SEQ ID NO: 40. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 39, and the VL comprises an amino acid sequence as set forth in SEQ ID NO: 40.

[0060] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as I38 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with I38 for binding to FAPα are also provided.

[0061] In some embodiments, the antibodies or antigen-binding fragments provided are derived from antibody J59. In some embodiments, the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 14, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 19, the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 26, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 30, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 33, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 38.

[0062] In some embodiments, one or more CDRs undergo PTM (post-translational modification) to reduce risk. In some embodiments, the VH CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 14, the VH CDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 19 and 56-58, the VH CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 26, the VL CDR1 comprises the amino acid sequence as shown in SEQ ID NO: 30, the VL CDR2 comprises the amino acid sequence as shown in SEQ ID NO: 33, and the VL CDR3 comprises the amino acid sequence as shown in SEQ ID NO: 38.

[0063] In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 41, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 41, while retaining the VH CDRs of SEQ ID NO: 41, or a PTM risk reassessed version thereof. In some embodiments, the VL comprises an amino acid sequence as set forth in SEQ ID NO: 42, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 42, while retaining the VL CDRs of SEQ ID NO: 42, or a PTM risk reassessed version thereof. In some embodiments, the VH comprises an amino acid sequence as set forth in SEQ ID NO: 41, and the VL comprises an amino acid sequence as set forth in SEQ ID NO: 42.

[0064] In some embodiments, antibodies and antigen-binding fragments that bind to the same epitope on FAPα as J59 are also provided. In some embodiments, antibodies and antigen-binding fragments that compete with J59 for binding to FAPα are also provided.

[0065] In some embodiments, antibodies and antigen-binding fragments are also provided that include CDR sequences derived from the presently disclosed CDR sequences, wherein there are one, two or three amino acid substitutions, deletions and / or additions.

[0066] Multifunctional molecules

[0067] Multifunctional molecules comprising an antibody or antigen-binding fragment specific for FAPa, such as those disclosed herein, and one or more antibodies or antigen-binding fragments specific for a second antigen.

[0068] In some embodiments, the second antigen is a protein expressed on immune cells, such as T cells, B cells, monocytes, macrophages, neutrophils, dendritic cells, phagocytes, natural killer cells, eosinophils, basophils, and mast cells.

[0069] In some embodiments, the second antigen is CD3, CD47, PD1, PD-L1, LAG3, TIM3, CTLA4, VISTA, CSFR1, A2AR, CD73, CD39, CD40, CEA, HER2, CMET, 4-1BB, OX40, SIRPA CD16, CD28, ICOS, CTLA4, BTLA, TIGIT, HVEM, CD27, VEGFR, or VEGF.

[0070] In addition, different forms of bispecific antibodies are also provided. In some embodiments, each anti-FAPα fragment and the second fragment are independently selected from a Fab fragment, a single-chain variable fragment (scFv) or a single domain antibody. In some embodiments, the bispecific antibody also includes an Fc fragment. Also provided are bifunctional molecules that include not only antibodies or antigen-binding fragments.

[0071] As tumor antigen targeting molecules, antibodies or antigen-binding fragments specific for FAPα, such as those described herein, can be selectively bound to immune cytokines or ligands through peptide linkers. The connected immune cytokines or ligands include, but are not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, GM-CSF, TNF-,, CD40L, OX40L, CD27L, CD30L, 4-1BBL, LIGHT, and GITRL. This bifunctional molecule can combine immune checkpoint blockade with local immune regulation at the tumor site.

[0072] Chimeric Antigen Receptor

[0073] In one embodiment, a chimeric antigen receptor (CAR) is also provided, which includes an antibody or fragment thereof disclosed herein as a targeting unit. In some embodiments, CAR includes an antibody or fragment thereof disclosed herein, a transmembrane domain, a costimulatory domain, and a CD3 ξ intracellular domain.

[0074] The transmembrane domain can be designed to be fused with the extracellular domain, optionally through the hinge domain, and the extracellular domain includes an antibody or a fragment. It can also be fused with an intracellular domain, such as a costimulatory domain. In some embodiments, the transmembrane domain may include a natural transmembrane region of a costimulatory domain (e.g., a TM region of CD28T or 4-1BB used as a costimulatory domain) or a natural transmembrane domain of a hinge region (e.g., a TM region of CD8α or CD28T used as a hinge domain).

[0075] In some embodiments, a transmembrane domain may include a sequence that spans the cell membrane but extends into the cytoplasm and / or the extracellular space of the cell. For example, a transmembrane may include a transmembrane sequence that itself may further include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids that extend into the cytoplasm and / or the extracellular space of the cell. Thus, a transmembrane domain includes a transmembrane region but may further include one or more amino acids that extend beyond the interior or exterior surface of the membrane itself; such sequences may still be considered "transmembrane domains".

[0076] In some embodiments, the transmembrane domain is fused to the cytoplasmic domain via a short peptide. Optionally, a short peptide or polypeptide connector (preferably between 2 and 10 amino acids in length) can form a connection between the transmembrane domain and the proximal cytoplasmic signaling domain of the chimeric receptor. Glycine-serine doublets (GS), glycine-serine-glycine triplet (GSG), or alanine-alanine-alanine triplet (AAA) provide suitable linkers.

[0077] In some embodiments, CAR also includes a costimulatory domain. In some embodiments, the costimulatory domain is located between the transmembrane domain and the activation domain. Exemplary costimulatory domains include, but are not limited to, CD2, CD3δ, CD3ε, CD3γ, CD4, CD7, CD8a, CD8β, CD11a (ITGAL), CD11b (ITGAM), CD11c (ITGAX), CD11d (ITGAD), CD18 (ITGB2), CD19 (B4), CD27 (TNFRSF7), CD28, CD28T, CD29 (ITGB1), CD30 (TNFRSF8), CD40 (TNFRSF5), CD48 (SLAMF2), CD49a (ITGA1), CD49d (ITGA4), CD49f (ITGA6), CD66a (CEACAM1), CD66b (CEACAM8), CD66c (CEACAM6), CD66d (CEACAM3), CD66e (CEACAM5), CD69 (CLEC2), CD79A (B cell antigen receptor complex-associated α chain), CD79B (B cell antigen receptor complex-associated β chain), CD84 (SLAMF5), CD96 (Tactile protein), CD100 (SEMA4D), CD103 (ITGAE), CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD 158A(KIR2DL1), CD158B1(KIR2DL2), CD158B2(KIR2DL3), CD158C(KIR3DP1), CD158D(KIR2DL4), CD158F1(KIR2DL5A), CD158F2(KIR2DL5B), CD 158K(KIR3DL2), CD160(BY55), CD162(SELPLG), CD226(DNAM1), CD229(SLAMF3), CD244(SLAMF4), CD247(CD3-zeta), CD258(LIGHT), CD268(BA FFR), CD270 (TNFSF14), CD272 (BTLA), CD276 (B7-H3), CD279 (PD-1), CD314 (NKG2D), CD319 (SLAMF7), CD335 (NKp46), CD336 (NKp44), CD337 (NKp30), CD352 (SLAMF6), CD353 (SLAMF8), CD355 (CRTAM), CD357 (TNFRSF18), inducible T cell co-stimulatory molecule (ICOS), LFA-1 (CD11a / CD18), NKG2C, DAP-10, ICAM-1,NKp80 (KLRF1), IL-2Rβ, IL-2Rγ, IL-7Rα, LFA-1, SLAMF9, LAT, GADS (GrpL), SLP-76 (LCP2), PAG1 / CBP, CD83 ligand, Fcγ receptor, MHC class I molecule, MHC class II molecule, TNF receptor protein, immunoglobulin, cytokine receptor, integrin, activated NK cell receptor, Toll-like receptor, and fragments or combinations thereof.

[0078] In some embodiments, the cytoplasmic portion of CAR also includes a signal transduction / activation domain. In one embodiment, the signal transduction / activation domain is a CD3 ξ domain, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity with a CD3 ξ domain.

[0079] Polynucleotides, mRNA, and methods for expressing or preparing antibodies

[0080] The present disclosure also provides polynucleotides or nucleic acid molecules encoding antibodies, variants or derivatives thereof or CARs of the present disclosure. The polynucleotides of the present disclosure can encode the entire heavy chain and light chain variable regions of antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide molecule or a separate polynucleotide molecule. In addition, the polynucleotides of the present disclosure can encode a portion of the heavy chain and light chain variable regions of antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide molecule or a separate polynucleotide molecule.

[0081] In some embodiments, the polynucleotide is an mRNA molecule. In some embodiments, the mRNA can be introduced into a target cell to express the antibody or fragment thereof.

[0082] mRNA can be synthesized according to various known methods. For example, mRNA can be synthesized by in vitro transcription (IVT). Briefly, IVT generally uses a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (such as T3, T7 or SP6 RNA polymerase), DNAse I, pyrophosphatase and / or RNAse inhibitor. The specific conditions will vary depending on the specific application.

[0083] In some embodiments, in order to prepare the mRNA encoding the antibody, it is necessary to transcribe the DNA template in vitro. Suitable DNA templates generally have a promoter for in vitro transcription, such as a T3, T7 or SP6 promoter, followed by a desired nucleotide sequence and termination signal for the desired antibody encoding (e.g., heavy chain or light chain encoding) mRNA.

[0084] The desired antibody encoding (such as heavy chain or light chain encoding) mRNA sequence can be determined using standard methods and integrated into the DNA template. For example, starting from the desired amino acid sequence (e.g., the desired heavy chain or light chain sequence), a virtual reverse translation is performed based on the degenerate genetic code. An optimization algorithm can then be used to select the appropriate codons. Typically, on the one hand, the G / C content can be optimized to achieve the highest possible G / C content, and on the other hand, the frequency of tRNA can be considered as much as possible based on the usage of the codons. The optimized RNA sequence can be established and displayed, for example, with the help of an appropriate display device and compared with the original (wild type) sequence. The stable and unstable properties or corresponding regions of RNA can also be calculated by analyzing the secondary structure.

[0085] mRNA can be synthesized as unmodified or modified mRNA. Typically, mRNA is modified to enhance stability. For example, the modification of mRNA may include modification of the nucleotides of the RNA. Thus, the modified mRNA may include, for example, backbone modifications, sugar modifications, or base modifications. In some embodiments, antibody encoding mRNA (e.g., heavy chain and light chain encoding mRNA) can be synthesized from naturally occurring nucleotides and / or nucleotide analogs (modified nucleotides), including but not limited to purines (adenine), or nucleotide analogs (modified nucleotides), including but not limited to purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and modified nucleotide analogs or derivatives of purines and pyrimidines, such as 1-methyladenine, 2-methyladenine, 2-methylthio-N-6-isopentenyladenine, N6-methyladenine, N6-isopentenyladenine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methylguanine, 2-methylguanine 2,2-dimethylguanine, 7-methylguanine, inosine, glycoside, 1-methylinosine, pseudouracil (5-uracil), dihydrouracil, 2-thiouracil, 4-thiouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil, 5-methyl-uracil, N-uracil-5-oxyacetate methyl ester, 5-methylaminomethyl-uracil, 5 -methoxyaminomethyl-2-thio-uracil, 5'-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 1-methylpseudouracil, quinoline, 13-D-mannosylquinoline and wybutoxosine, as well as phosphoamidates, thiophosphates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine. Methods for preparing such analogs are known to those skilled in the art, for example, see U.S. Patent Nos. 4,373,071, 4,401,796, 4,415,732, 4,458,066, 4,500,707, 4,668,777, 4,973,679, 5,047,524, 5,132,418, 5,153,319, 5,262,530 and 5,700,642, the entire contents of which are incorporated herein by reference.

[0086] In some embodiments, mRNA (e.g., heavy chain and light chain encoding mRNA) may include RNA backbone modifications. Typically, backbone modifications refer to chemical modifications of the phosphates of the nucleotide backbones contained in the RNA. Exemplary backbone modifications typically include, but are not limited to, modifications of groups consisting of methylphosphonates, methylphosphoamidates, phosphoramidites, thiophosphates (e.g., cytidine 5'-O-(1-thiophosphoric acid)), borophosphates, positively charged guanidine groups, etc., which means replacing the phosphodiester bonds with other anions, cations, or neutral groups.

[0087] In some embodiments, mRNA (e.g., heavy chain and light chain encoding mRNA) may contain sugar modifications. Typical sugar modifications are chemical modifications of the sugars of the nucleotides contained therein, including but not limited to 2'-deoxy-2'-fluoro oligonucleotides (2'-fluoro-2'-deoxycytidine 5'-triphosphate, 2'-fluoro-2'-deoxyuridine 5'-triphosphate), 2'-deoxy-2'-deamine oligonucleotides (2'-amino-2'-deoxycytidine 5'-triphosphate, 2'-amino-2'-deoxyuridine 5'-triphosphate), 2'-O-alkyl oligosaccharide nucleotides, Sugar modifications from the group consisting of 2'-deoxy-2'-C-alkyl oligosaccharide nucleotides (2'-O-methylcytidine 5'-triphosphate, 2'-methyluridine 5'-triphosphate), 2'-C-alkyl oligosaccharide nucleotides and their isomers (2'-aromatic glycoside 5'-triphosphate, 2'-aromatic uridine 5'-triphosphate) or azidotriphosphates (2'-azido-2'-deoxycytidine 5'-triphosphate, 2'-azido-2'-deoxyuridine 5'-triphosphate).

[0088] In some embodiments, mRNA (such as heavy chain and light chain encoding mRNA) may contain modifications of nucleotide bases (base modifications). Modified nucleotides containing base modifications are also referred to as base modified nucleotides. Examples of such base modified nucleotides include, but are not limited to, 2-amino-6-chloropurine nucleoside 5'-triphosphate, 2-aminoadenosine 5'-triphosphate, 2-thiocytidine 5'-triphosphate, 2-thiouridine 5'-triphosphate, 4-thiouridine 5'-triphosphate, 5-aminoallylcytidine 5'-triphosphate, 5-aminoallylcytidine 5'-triphosphate, 5-bromocytidine 5'-triphosphate, 5-bromouridine 5'-triphosphate, 5-iodocytidine 5'-triphosphate, 5-iodouridine 5'-triphosphate, 5-methylcytidine 5'-triphosphate, 5-methyluridine 5'-triphosphate. , 6-azacytidine 5'-triphosphate, 6-azauridine 5'-triphosphate, 6-chloropurine nucleoside 5'-triphosphate, 7-deazaadenosine 5'-triphosphate, 7-deazaguanosine 5'-triphosphate, 8-azaadenosine 5'-triphosphate, 8-azidoadenosine 5'-triphosphate, benzimidazole nucleoside 5'-triphosphate, N1-methyladenosine 5'-triphosphate, N1-methylguanosine 5'-triphosphate, N6-methyladenosine 5'-triphosphate, O6-methylguanosine 5'-triphosphate, pseudouridine 5'-triphosphate, puromycin 5'-triphosphate or xanthosine 5'-triphosphate.

[0089] Typically, the synthesis of mRNA involves the addition of a "cap" at the N(5') terminus and a "tail" at the C(3') terminus. The presence of the cap is important for protection against nucleases found in most eukaryotic cells. The presence of the "tail" protects the mRNA from degradation by exonucleases.

[0090] Thus, in some embodiments, the mRNA (e.g., heavy and light chain encoding mRNA) includes a 5' cap structure. The 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one terminal phosphate group from the 5' nucleotide, leaving two terminal phosphates; then guanosine triphosphate (GTP) is added to the terminal phosphate by a guanylate transferase, resulting in a 5'5'5 triphosphate linkage; then the 7-nitrogen of guanine is methylated by a methyltransferase. Examples of cap structures include, but are not limited to, m7G(5')ppp(5'(A, G(5')ppp(5)A, and G(5)pp(5')G.

[0091] In some embodiments, mRNA (e.g., heavy and light chains encoding mRNA) includes a 3'poly (A) tail structure. The poly-A tail at the 3' end of the mRNA generally includes about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 175 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 125 adenosine nucleotides, 10 to 100 adenosine nucleotides, about 10 to 75 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). In some embodiments, antibody encoding mRNA (e.g., heavy and light chain encoding mRNA) includes a 3'poly (C) tail structure. A suitable 3' terminal poly-C tail of mRNA generally includes about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The poly-C tail can be added to the poly-A tail or can replace the poly-A tail.

[0092] In some embodiments, mRNA (e.g., heavy chain and light chain encoding mRNA) includes 5' and / or 3' untranslated regions. In some embodiments, the 5' untranslated region includes one or more elements that affect mRNA stability or translation, for example, an iron response element. In some embodiments, the length of the 5' untranslated region may be between about 50 and 500 nucleotides (e.g., a length of about 50 and 400 nucleotides, a length of about 50 and 300 nucleotides, a length of about 50 and 200 nucleotides, or a length of about 50 and 100 nucleotides).

[0093] In some embodiments, the 5' region of the mRNA (e.g., heavy and light chain encoding mRNA) includes a sequence encoding a signal peptide, such as those described herein. In a specific embodiment, a signal peptide derived from human growth hormone (hGH) is integrated into the 5' region. Typically, the signal peptide coding sequence is directly or indirectly connected to the heavy chain or light chain coding sequence at the N-terminus.

[0094] The present technology can be used to deliver any antibody known in the art and antibodies against a desired antigen that can be generated using standard methods. The present invention can be used to deliver monoclonal antibodies, polyclonal antibodies, antibody mixtures or cocktail antibodies, human or humanized antibodies, chimeric antibodies or bispecific antibodies.

[0095] Methods for preparing antibodies are well known in the art and are also described herein. In some embodiments, the variable regions and constant regions of the antigen-binding polypeptides disclosed herein are all fully human. Fully human antibodies can be prepared using techniques described in the art and methods described herein. For example, fully human antibodies against a specific antigen can be prepared by injecting an antigen into a transgenic animal that has been modified to produce such an antibody in response to an antigenic challenge, but whose endogenous gene sites have been disabled. Exemplary techniques for preparing such antibodies are described in U.S. Patents 6,150,584; 6,458,592; 6,420,140, ​​which are incorporated herein by reference in their entirety.

[0096] Treatment and uses

[0097] As described herein, the antibodies, variants, derivatives or antibody-drug conjugates of the present disclosure may be used in certain therapeutic and diagnostic methods.

[0098] The present disclosure is further directed to antibody-based therapies involving administration of the disclosed antibodies, fragments or antibody-drug conjugates to patients such as animals, mammals and humans to treat one or more diseases or conditions described herein. Therapeutic compounds of the present disclosure include, but are not limited to, antibodies of the present disclosure (including variants and derivatives thereof as described herein) and nucleic acids or polynucleotides encoding antibodies of the present disclosure (including variants and derivatives thereof as described herein).

[0099] The antibodies disclosed herein can also be used to treat or inhibit cancer. As described above, FAPα can be overexpressed in tumor cells, particularly liver cancer, gastric cancer, pancreatic cancer, esophageal cancer, ovarian cancer and lung cancer. Inhibition of FAPα has been shown to be useful for treating tumors.

[0100] Thus, in some embodiments, methods for treating cancer in a patient in need thereof are provided. In one embodiment, the method entails administering to the patient an effective amount of an antibody, fragment, or antibody-drug conjugate of the disclosure. In some embodiments, at least one cancer cell (e.g., stromal cell) of the patient overexpresses FAPα.

[0101] Cell therapy, such as chimeric antigen receptor (CAR) T cell therapy, is also provided in the present disclosure. Suitable cells can be used, transduced with a vector encoding CAR, or contacted with CAR, which includes an anti-FAPα antibody disclosed herein (or alternatively, engineered to express an anti-FAPα antibody disclosed herein). After such contact or engineering design, cells can be introduced into a cancer patient in need of treatment. Cancer patients may suffer from any type of cancer disclosed herein. For example, cells (such as T cells) can be, for example, tumor infiltrating T lymphocytes, CD4+T cells, CD8+T cells, or a combination thereof, but are not limited.

[0102] In some embodiments, the cells are isolated from the cancer patient himself. In some embodiments, the cells are provided by a donor or from a cell bank. When the cells are isolated from the cancer patient, unnecessary

[0103] Non-limiting examples of cancer include bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer and thyroid cancer. In some embodiments, the cancer is one or more of gastric cancer, pancreatic cancer, esophageal cancer, ovarian cancer and lung cancer.

[0104] The antibodies or variants or derivatives thereof disclosed herein can be used for the treatment, prevention, diagnosis and / or prognosis of other diseases or conditions associated with increased cell survival, including, but not limited to, the progression and / or metastasis of malignancies and related diseases, such as leukemias (including acute leukemias (such as acute lymphocytic leukemia, acute myeloid leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia)) and chronic leukemias (such as chronic myeloid leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (such as Hodgkin's disease and non-Hodgkin's lymphoma), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors, including, but not limited to, sarcomas and cancers, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, Chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovial sarcoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, liver cancer, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumors, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

[0105] FAPα is involved in controlling epithelial-mesenchymal interactions during fibroblast growth or development, tissue repair, and epithelial carcinogenesis. Studies have found that high expression of FAPα in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) is associated with the invasive phenotype, high proliferation, and destruction of the extracellular matrix of FLS. Therefore, FAPα can be considered a therapeutic target to inhibit the destructive potential of FLS.

[0106] In addition, methods and uses for treating inflammatory conditions or autoimmune diseases are also provided. In some embodiments, the inflammatory diseases or conditions to be treated by the disclosed antibodies, fragments and compositions include one or more of Alzheimer's disease, Addison's disease, atherosclerosis, ankylosing spondylitis, arthritis, osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease (COPD), Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease (PD), vasculitis and ulcerative colitis.

[0107] In some embodiments, the autoimmune diseases or conditions to be treated by the disclosed antibodies, fragments and compositions include one or more of the following diseases: alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes (type 1), celiac disease, autoimmune juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, autoimmune myocarditis, multiple sclerosis, pemphigus / pemphigoid, malignant Anemia, polyarteritis nodosa, polymyositis, myasthenia gravis, autoimmune myocarditis, multiple sclerosis, papular urticaria / papular urticaria, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's disease).

[0108] Rheumatoid arthritis (RA) is a long-term autoimmune disease that primarily affects the joints. It typically causes warmth, swelling, and pain in the joints. The pain and stiffness tend to get worse after rest. The wrists and hands are most commonly affected, and often the same joints on both sides of the body are affected. The disease may also affect other parts of the body. Although the cause of RA is unknown, it is generally believed that it involves a combination of genetic and environmental factors. Its underlying mechanism involves the body's immune system attacking the joints. This causes inflammation of the joints and thickening of the joint capsule. The goal of treatment is to relieve pain, reduce inflammation, and improve the patient's overall function. Painkillers, steroids, and nonsteroidal anti-inflammatory drugs are often used to relieve symptoms. A class of drugs called disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, can be used to try to slow the progression of the disease.

[0109] The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the specific antibody, variant or derivative thereof used, the patient's age, weight, general health, sex and diet, as well as the time of administration, excretion rate, drug combination and the severity of the specific disease being treated. The judgment of such factors by medical care personnel belongs to the ordinary technical level in this field. The dosage also depends on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease and the expected effect. The dosage used can be determined by pharmacological and pharmacokinetic principles known in the art.

[0110] The method of administration of antibodies, fragments or antibody-drug conjugates includes but is not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral routes. Antigen-binding polypeptides or compositions can be administered by any convenient route, such as by infusion or rapid injection, absorption by epithelial or mucosal epithelial lining (such as oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other bioactive agents. Therefore, pharmaceutical compositions containing antigen-binding polypeptides of the present disclosure can be administered orally, rectally, parenterally, intrathecally, intravaginally, intraperitoneally, topically (such as in the form of powders, ointments, drops or transdermal patches), oral mucosal administration or as oral or nasal sprays.

[0111] The term "parenteral" as used herein refers to routes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injections and infusions.

[0112] The administration method can be systemic administration or local administration. In addition, the antibodies of the present disclosure can be introduced into the central nervous system by any appropriate route, including intraventricular injection and intrathecal injection; for example, intraventricular injection can be performed by an intraventricular catheter connected to a reservoir (such as an Ommaya reservoir). Pulmonary administration can also be used, for example, by using an inhaler or nebulizer, and using an aerosol formulation.

[0113] The antigen-binding polypeptides or compositions disclosed herein can be applied to the site in need of treatment by topical administration; for example (but not limited to) administration by local perfusion during surgery, topical application (such as in combination with postoperative dressings), injection, catheter, suppository or implant, the implant can be porous, non-porous or gelatinous material, including membranes (such as silicone membranes) or fibers. Preferably, when administering the disclosed proteins (including antibodies), care must be taken to use materials that are not absorbed by the protein.

[0114] The effective amount of the disclosed antibodies, fragments or antibody-drug conjugates in treating, inhibiting and preventing inflammatory, immune or malignant diseases, disorders or conditions can be determined by standard clinical techniques. In addition, in vitro assays can be used to help determine the optimal dosage range. The precise dose used in the formulation also depends on the route of administration and the severity of the disease, disorder or condition, and should be determined based on the doctor's judgment and the circumstances of each patient. The effective dose can be inferred from a dose-response curve derived from an in vitro or animal model test system.

[0115] As a general principle of administration, the dosage of the disclosed antibodies, antibody fragments or antibody-drug conjugates administered to patients is generally: 0.001 mg / kg to 100 mg / kg of patient body weight; or 0.01 mg / kg to 20 mg / kg of patient body weight; or 0.5 mg / kg to 10 mg / kg of patient body weight. In general, due to the immune response to exogenous polypeptides, human antibodies have a longer half-life in the human body than antibodies of other species. Therefore, the dose of human antibodies can usually be reduced and the number of administrations can be reduced. In addition, the uptake and tissue penetration ability (e.g., into the brain) of the disclosed antibodies can be enhanced by using modifications such as lipidation, thereby reducing the dosage and frequency of administration of the disclosed antibodies.

[0116] In another embodiment, the compositions of the present disclosure are administered in combination with cytokines. Cytokines that can be administered with the compositions of the present disclosure include, but are not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, anti-CD40, CD40L, and TNF-.

[0117] In other embodiments, the compositions disclosed herein can be used in conjunction with other therapeutic or preventive regimens, such as radiation therapy.

[0118] Composition

[0119] The present disclosure also provides a pharmaceutical composition. This composition is composed of an effective amount of an antibody, fragment or antibody-drug conjugate and an acceptable carrier. In some embodiments, the composition also includes a second anticancer agent (e.g., an immune checkpoint inhibitor).

[0120] In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the federal or state government, or listed in the United States Pharmacopeia or other recognized pharmacopeia, for use in animals, particularly for use in humans. In addition, a "pharmaceutically acceptable carrier" is generally a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or any type of formulation auxiliary.

[0121] The term "carrier" refers to a diluent, adjuvant, excipient or vehicle for administering a therapeutic agent. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including oils of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is injected intravenously, water is the preferred carrier. Physiological saline, aqueous glucose solution and aqueous glycerol solution can also be used as liquid carriers, especially for injection solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If necessary, the composition can also contain a small amount of a wetting agent or emulsifier, or a pH buffer, such as acetate, citrate or phosphate. The present disclosure also relates to the use of the following excipients: antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; and substances that regulate osmotic pressure, such as sodium chloride or glucose. These compositions can be in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release preparations, and the like. The composition can be formulated as a suppository, using conventional binders and carriers, such as triglycerides. The oral formulations of the present disclosure may contain conventional carriers, including but not limited to pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. For examples of suitable pharmaceutical carriers, see Remington's Pharmaceutical Sciences by EW Martin, the entire contents of which are incorporated herein by reference and constitute a part of this specification. Such a composition will contain a therapeutically effective amount of an antigen-binding polypeptide, preferably in a purified form, and an appropriate amount of a carrier to provide a suitable administration form for the patient. The formulation should be compatible with the mode of administration. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0122] In one embodiment, the composition is formulated into a pharmaceutical composition suitable for human intravenous injection according to conventional procedures. Generally, the composition for intravenous administration is dissolved in a sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizer and a local anesthetic, such as lidocaine, to relieve pain at the injection site. In general, these components may be provided separately or mixed together in a unit dose form, for example, as a dry lyophilized powder or anhydrous concentrate, sealed in a sealed container such as an ampoule or a pouch, and the amount of the active ingredient is indicated. If administration is to be performed by infusion, an infusion bottle containing sterile medicinal water or saline may be used. If the composition is administered by injection, an ampoule of sterile water for injection or saline may be provided to mix the components before administration.

[0123] The compounds of the present disclosure can be formulated into neutral form or salt form. Pharmaceutically acceptable salts include salts formed with anions, such as hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc., and salts formed with cations, such as sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.

[0124] Example 1: Screening and screening of a fully human natural phage library

[0125] In this example, fully human antibodies against FAPα were screened from a human natural phage library. Antigen: human FAPα-His tag (Sino Biological). Preparation of fully human natural phage library:

[0126] The phage library was constructed using phage vectors consisting of antibody gene fragments amplified from peripheral blood mononuclear cells (PBMCs) of healthy human subjects. The library was in the form of a Fab phage library with a library size of 5.2×10 10 .

[0127] Solid phase screening and solution screening of phage libraries against human FAPα protein. For solution screening, the phage library was first negatively screened by incubation with BSA-coated streptavidin Dynabeads magnetic beads. The resulting phage was incubated with biotinylated FAPα-His tagged protein and washed with Kingfisher magnetic bead system. The conjugate was eluted by trypsin. For solid phase screening, the phage library was first negatively blocked with 5% PBSM. The resulting phage was incubated with FAPα-His tagged protein and washed with PBST+PBS. The conjugate was eluted by trypsin.

[0128] Solid phase screening was combined with solution screening to comprehensively screen potential binders. The eluted phages were subsequently tested for binding antigen titer and co-cultured with E. coli. There were five rounds of screening and selection. The output titers of the fourth and fifth rounds increased significantly.

[0129] Single clones were selected from the output of the fourth and fifth rounds and then cultured in 96-well plates. The culture supernatants were evaluated for IgG concentration and antigen binding titer. A total of 390 positive clones were screened and sequenced. Sequence analysis identified 176 unique sequences. ELISA binding analysis was performed on all of these clones. The seven optimal sequences are listed in the table below. Their sequences are shown in Table 1A below.

[0130] Table 1A. Candidate antibody sequences

[0131]

[0132]

[0133]

[0134] The CDR sequences of these antibodies (according to the Kabat system) are listed in Table 1B. Also shown are their variants, in which potential post-translational modification (PTM) sites are mutated to bioequivalent sites (such as NG=>NA, NG=>QG, NS=>NA, NS=>QS, DG=>DA and DS=>DA). These substitutions are intended to retain the biological activity of the antibody while preventing PTM to facilitate production.

[0135] Table 1B. CDR sequences

[0136]

[0137]

[0138]

[0139] Underlined residues are substituted residues to prevent post-translational modification (PTM)

[0140] Some of these antibodies, particularly G14, G52, I30, I37 and J40, have highly homologous VH CDR1 and VL CDR sequences. These CDR sequences are considered interchangeable. Their alignment and consensus sequences are shown in Table 1C below.

[0141] Table 1C. Consensus CDR sequences

[0142]

[0143]

[0144] Example 2: Binding activity to human and mouse FAPα antigen

[0145] This example tests the binding activity of antibodies to human and mouse FAPa proteins.

[0146] 2.1 ELISA binding to human FAPα

[0147] To assess the binding activity of the clones, ELISA assays were performed with the test antibodies.

[0148] Briefly, human FAP-His protein was dissolved in PBS at 0.5 μg / ml, 100 μl / well, and coated on microplates overnight at 4°C. Subsequently, 150 μl / well of 1% bovine serum albumin (BSA) was added for blocking. Three-fold dilutions of antibodies starting from 1 ug / ml were added to each well and incubated at 37°C for 1 hour. The plate was washed with PBS / Tween and then incubated with peroxidase-conjugated anti-human IgG (H&L) (goat) antibody at 37°C for 30 minutes. After washing, the plate was developed with TMB substrate and analyzed with a spectrophotometer at OD 450nm wavelength. Figure 1 As shown in Figure A and Table 2, all G14, G52, I30, I37, I38, J40 and J59 clones bind to human FAPα with high affinity. Roche's FAP-4B9 clone was used as a positive control and was labeled as FAPα-BMK.

[0149] 2.1 ELISA binding to mouse FAPα

[0150] To assess the binding activity of the clones, ELISA assays were performed with the test antibodies.

[0151] Briefly, mouse FAP-His protein was dissolved in PBS at 0.5 μg / ml, 100 μl / well, and coated on microtiter plates overnight at 4°C. Subsequently, 150 μl / well of 1% bovine serum albumin (BSA) was added for blocking. Three-fold dilutions of antibodies starting from 1 ug / ml were added to each well and incubated at 37°C for 1 hour. The plates were washed with PBS / Tween and then incubated with peroxidase-conjugated anti-human IgG (H&L) (goat) antibodies at 37°C for 30 minutes. After washing, the plates were developed with TMB substrate and analyzed with a spectrophotometer at OD 450nm. Figure 1 B and as shown in Table 2 , only I37 and FAPα-BMK bound to mouse FAPα with high affinity.

[0152] Table 2. Binding activity to human and mouse FAPα

[0153]

[0154]

[0155] 2.2 Cellular binding to human FAPα

[0156] To evaluate the cellular binding properties to human FAPα, the binding of the test antibodies to CHO-K1-hFAPα was analyzed by FACS. 5Each CHO-K1-hFAPα cell was incubated with 4-fold serial dilutions of the antibody starting at 3 μg / ml in FACS buffer for 30 min. After washing with FACS buffer, PE-conjugated anti-human IgG antibody was added to each well and incubated at 4°C for 30 min. After washing, the MFI of PE was evaluated using a MACSQuant Analyzer 16. Figure 2 As shown in Table 3, G14, I30, I37 and J40 antibodies showed binding abilities comparable to the positive reference "FAPαBMK antibody", while I38 and J59 clones significantly reduced binding activity.

[0157] Table 3. Binding activity to CHO-K1-hFAPα cells

[0158] Antibody EC50(ng / ml) Cmax FAPα-BMK 0.043 423.6 G14 0.073 515.1 I30 0.080 455.2 I37 0.057 464.7 J40 0.025 380.6 I38 0.026 188.6 J59 0.029 148.7

[0159] 2.3 Comprehensive kinetic analysis of human FAPα protein

[0160] The binding of the test antibody to the recombinant FAPα protein (human FAPα-His tagged protein) was tested using Biacore using the capture method. The antibody was captured by a protein A chip. A gradient dilution of human FAPα-His tagged protein was injected onto the captured antibody at a flow rate of 30μl / min for 3 minutes. The antigen was then allowed to dissociate for 800 seconds. All experiments were performed on a Biacore T200 instrument. Data analysis was completed using the Biacore T200 evaluation software. The results are as follows Figure 3 And as shown in Table 4.

[0161] Table 4: Comprehensive kinetic parameters measured by Biacore

[0162]

[0163] Example 3: Epitope grouping by competition ELISA

[0164] Competition ELISA was used to classify FAPα monoclonal antibodies based on their binding epitope to human FAPα.

[0165] Briefly, human FAPα protein was dissolved in PBS at 0.5 μg / ml, 100 μl / well was added, and the microplate was coated overnight at 4°C. Subsequently, 150 μl / well of 1% bovine serum albumin (BSA) was added for blocking. Serial dilutions of chimeric antibodies and biotin-conjugated reference monoclonal antibodies were added to each well and incubated for 1 hour at room temperature. The microplate was washed with PBS / Tween and then incubated with streptavidin-HRP for 15 minutes at room temperature. After washing the plate, color was developed with TMB substrate and analyzed with a spectrophotometer at OD450nm wavelength. Based on the competitive ability with the reference monoclonal antibody (benchmark antibody, or "BMK"), all tested FAPα monoclonal antibodies bind to similar epitopes as shown in Table 5.

[0166] Table 5: Epitope grouping test using ELISA

[0167]

[0168]

[0169] The present disclosure is not limited to the scope of the specific embodiments described, which are intended to be a single illustration of the various aspects of the present disclosure, and any compositions or methods that are functionally equivalent are within the scope of the present disclosure. It will be appreciated by those skilled in the art that various modifications and variations may be made to the methods and compositions of the present disclosure without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure is intended to encompass modifications and variations of the present disclosure that fall within the scope of the appended claims and their equivalents.

[0170] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Claims

1. An antibody or antigen-binding fragment thereof, which is specific to human fibroblast activation protein alpha (FAPα), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises VH CDR1, VH CDR2 and VHCDR3, and the light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-17 and 43-55; The VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-23, 25, 59 and 60; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 43-48; The VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 59 and 60; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

3. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 11; The VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 43-48; The VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 59 and 60; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 61 and 62.

4. The antibody or antigen-binding fragment thereof according to claim 3, wherein The VH comprises the amino acid sequence shown in SEQ ID NO:1, and the VL comprises the amino acid sequence shown in SEQ ID NO:

2.

5. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 and 49-54; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:21; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

6. The antibody or antigen-binding fragment thereof according to claim 5, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; The VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 and 49-54; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO:21; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 28; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 35, 63 and 64.

7. The antibody or antigen-binding fragment thereof according to claim 6, wherein The VH comprises the amino acid sequence shown in SEQ ID NO:3, and the VL comprises the amino acid sequence shown in SEQ ID NO:

4.

8. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

9. The antibody or antigen-binding fragment thereof according to claim 8, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 22; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 61 and 62.

10. The antibody or antigen-binding fragment thereof according to claim 9, wherein The VH comprises the amino acid sequence shown in SEQ ID NO:5, and the VL comprises the amino acid sequence shown in SEQ ID NO:

6.

11. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 23; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

12. The antibody or antigen-binding fragment thereof according to claim 11, wherein: The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 23; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 36, 65 and 66.

13. The antibody or antigen-binding fragment thereof according to claim 12, wherein The VH comprises the amino acid sequence shown in SEQ ID NO:7, and the VL comprises the amino acid sequence shown in SEQ ID NO:

8.

14. The antibody or antigen-binding fragment thereof according to claim 1, wherein The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO:67; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO:68; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence shown in SEQ ID NO:

69.

15. The antibody or antigen-binding fragment thereof according to claim 14, wherein The VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; The VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 or 55; The VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; The VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 27; The VL CDR2 comprises the amino acid sequence shown in SEQ ID NO:31; and The VL CDR3 comprises the amino acid sequence as shown in the group consisting of SEQ ID NO:34, 61 and 62.

16. The antibody or antigen-binding fragment thereof according to claim 15, wherein The VH comprises the amino acid sequence shown in SEQ ID NO:9, and the VL comprises the amino acid sequence shown in SEQ ID NO:

10.

17. The antibody or fragment thereof according to any one of claims 1 to 16, wherein the antibody or fragment thereof is a bivalent Fab antibody, or a fragment selected from the group consisting of F(ab')2, F(ab)2, Fab', Fab, Fv and scFv.

18. A multispecific antibody comprising the antigen-binding fragment of any one of claims 1 to 17 and one or more antibodies or antigen-binding fragments having binding specificity to a target antigen other than FAPa.

19. A chimeric antigen receptor (CAR), comprising an antigen binding fragment as described in any one of claims 1-17, a transmembrane domain, a co-stimulatory domain and a CD3ξ intracellular domain.

20. One or more polynucleotides encoding the antibody or antigen-binding fragment thereof as described in any one of claims 1-18 or the CAR as described in claim 19.

21. The polynucleotide of claim 20, which is one or more mRNAs.

22. The polynucleotide of claim 21, wherein the mRNA is chemically modified.

23. A cell comprising the polynucleotide of claim 20.

24. A composition comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-18 or the CAR as described in claim 19, and a pharmaceutically acceptable carrier.

25. A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of the antibody or antigen-binding fragment thereof as described in any one of claims 1-18 or the CAR as described in claim 19.

26. Use of the antibody or antigen-binding fragment thereof as described in any one of claims 1 to 18 or the CAR as described in claim 19 in the preparation of a medicament for treating cancer.

27. A method of treating an inflammatory disorder in a patient in need thereof, comprising administering to the patient an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-18.

28. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 18 in the preparation of a medicament for treating an inflammatory disorder.

29. The method of claim 27 or the use of claim 28, wherein The inflammatory condition is associated with rheumatoid rhinitis (RA).

Citation Information

Patent Citations

  • Protein formulations

    CN101426527A

  • DNA based on FAPalpha and survivin and application of DNA based on FAPalpha and survivin in production of tumor vaccine

    CN111118063A